• O. Glavatskyi State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine
  • N. Khranovska State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • O. Skachkova State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • O. Gorbach State Non-commercial Enterprise “National Cancer Institute”, Kyiv, Ukraine
  • H. Khmelnytskyi State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine
  • I. Shuba State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine
  • Ye. Pedachenko State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine
  • O. Zemskova State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine
  • O. Zemskova State Institution "Academician Romodanov Institute of Neurosurgery, the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine



glioblastoma, immunotherapy, dendritic cell vaccination, survival


Glioblastoma (GBM) is the most aggressive primary malignant brain tumor in adults. The improvement of the efficacy of GBM treatment is an urgent problem encouraging the development of novel therapeutic strategies, in particular, immunotherapeutic modalities. With more understanding of the intimate interrelationships between the immune system and the mechanisms involved in cancer origin and progression, the skepticism related to the relevance of the immunotherapeutic approaches in the treatment of brain tumors is gradually decreasing. The review discloses the modern concepts on the association between CNS and the immune system. For a long time, CNS was considered as the immunoprivileged site that prevents the effects of immunotherapy in the treatment of brain tumors. Nowadays, these views are reconsidered, which opens the way to the use of immunotherapeutic approaches in GBM treatment. The results of the recent clinical trials on immunotherapy as a supplement to the conventional GBM treatment are considered. Vaccines based on the dendritic cell (DC) technology are regarded as the most promising for this purpose. The preliminary results of the Ukrainian clinical study are also presented and discussed. The results of the international clinical trials as well as our own experience give evidence of the relevance for using DC vaccines in the complex treatment of GBM, which is supported by the increased survival of patients and the safety of vaccine application. It is of high importance that GBM patients with the most unfavorable prognosis can benefit from DC vaccines as a component of the complex treatment. The prospects for immunotherapy in neurooncology are discussed.


Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key clinical principles in the management of glioblastoma. JCO Oncol Pract. 2023;19(4):180-189.

Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022;128(1):47-58.

Olivier C, Oliver L, Lalier L, Vallette FM. Drug resistance in glioblastoma: the two faces of oxidative stress. Front Mol Biosci. 2021;7:620677.

Tan AC, Ashley DM, López GY, et al. Management of glioblastoma: State of the art and future directions. CA Can­ cer J Clin. 2020;70(4):299-312.

Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021. CA Can­ cer J Clin. 2021;71(5):381-406.

Asija S, Chatterjee A, Yadav S, et al. Combinatorial approaches to effective therapy in glioblastoma (GBM): Cur- rent status and what the future holds. Int Rev Immunol. 2022;41(6):582-605. 22.2101647

Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstruct- ing antitumor immune responses. Front Immunol. 2020;11:940.

Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112-121.

Yu MW, Quail DF. Immunotherapy for glioblastoma: current progress and challenges. Front Immunol. 2021;12:676301. Erratum in: Front Immunol. 2021 Oct 07;12:782687.

Frederico SC, Hancock JC, Brettschneider EES, et al. Making a cold tumor hot: the role of vaccines in the treat- ment of glioblastoma. Front Oncol. 2021;11:672508. 10.3389/fonc.2021.672508

Omuro A, Brandes AA, Carpentier AF, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neu­ ro Oncol. 2023;25(1):123-134. 10.1093/neuonc/noac099

Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applica- tions. Trends Immunol. 2022;43(7):523-545. 10.1016/

Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to sub- cutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29(1):58-69.

Nicholas MK, Antel JP, Stefansson K, Arnason BG. Rejection of fetal neocortical neural transplants by H-2 in- compatible mice. J Immunol. 1987;139(7):2275-2283.

Billingham RE, Brent L, Medawar PB, Sparrow EM. Quantitative studies on tissue transplantation immunity.

I. The survival times of skin homografts exchanged between members of different inbred strains of mice. Proc R Soc Lond B Biol Sci. 1954;143(910):43-58. 10.1098/rspb.1954.0053.

Kim IK, Bedi DS, Denecke C, et al. Impact of innate and adaptive immunity on rejection and tolerance. Trans­ plantation. 2008;86(7):889-894. 10.1097/TP.0b013e318186ac4a

Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol. 2008;67(12):1113-1121. 10.1097/NEN.0b013e31818f9ca8

Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111. 10.1126/scitranslmed.3003748

Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-341. 10.1038/nature14432

Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The glymphatic system: a beginner's guide. Neurochem Res. 2015;40(12):2583-2599.

Bajénoff M, Germain RN. Seeing is believing: a focus on the contribution of microscopic imaging to our understan- ding of immune system function. Eur J Immunol. 2007;37 (Suppl 1):S18-S33.

Bartholomäus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature. 2009;462(7269):94-98.

Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010 May;120(5):1368-1379.

Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991-999. 10.1084/jem.20142290

Kipnis J. Multifaceted interactions between adaptive immunity and the central nervous system. Science. 2016;353(6301):766-771.

Radjavi A, Smirnov I, Derecki N, Kipnis J. Dynamics of the meningeal CD4(+) T-cell repertoire are defined by the cervical lymph nodes and facilitate cognitive task performance in mice. Mol Psychiatry. 2014;19(5):531- 533.

Rustenhoven J, Drieu A, Mamuladze T, et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell. 2021;184(4):1000-1016.e27. 10.1016/j.cell.2020.12.040

Brettschneider, EES, Masaki T. The role of NKT cells in glioblastoma. Cells. 2021;10(7):1641. 10.3390/cells10071641.

Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.

Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959- 1972.

Larsson HB, Stubgaard M, Frederiksen JL, et al. Quantitation of blood-brain barrier defect by magnetic reso- nance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990;16(1):117-131.

Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100(3):323-331. https://doi. org/10.1007/s004010000180

Wolburg H, Wolburg-Buchholz K, Kraus J, et al. Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multi- forme. Acta Neuropathol. 2003;105(6):586-592.

Bowman RL, Klemm F, Akkari L, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 2016;17(9):2445-2459.

Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical as- sessment of existing clinical data. Neuro Oncol. 2018;20(2):184-191.

Cozzi S, Najafi M, Gomar M, et al. Delayed effect of dendritic cells vaccination on survival in glioblastoma: a sys- tematic review and meta-analysis. Curr Oncol. 2022;29(2):881-891.

Huang Q, Pan X, Zhu W, et al. Natural products for the immunotherapy of glioma. Nutrients. 2023;15(12):2795.

Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. Adv Immunol. 1994;57:281-351. https://doi. org/10.1016/s0065-2776(08)60675-6

Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature. 1995;375(6527):151-155.

Tjoa B, Boynton A, Kenny G, et al. Presentation of prostate tumor antigens by dendritic cells stimu- lates T-cell proliferation and cytotoxicity. Prostate. 1996;28(1):65-69. 0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N

Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol. 1997;159(2):770- 776.

Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011;26(1):1-64. cbr.2010.0902

Matsuo K, Osamu Y, Kosuke K, et al. Recent progress in dendritic cell-based cancer immunotherapy. Cancers (Basel). 2021;13(10):2495.

Liu J, Fu M, Wang M, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.

J Hematol Oncol. 2022;15(1):28.

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

N Engl J Med. 2010;363(5):411-422.

Lowe J, MacLennan KA, Powe DG, et al. Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells. J Pathol. 1989;159(2):143-149. path.1711590209

Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239(4837):290-292. 10.1126/science.3276004

Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflam- mation. J Immunol. 2001;166(4):2717-2726. 10.4049/jimmunol.166.4.2717

Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.

Batich KA, Swartz AM, Sampson JH. Enhancing dendritic cell-based vaccination for highly aggressive glioblas- toma. Expert Opin Biol Ther. 2015;15(1):79-94. 10.1517/14712598.2015.972361

Wculek SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Im­ munol. 2020;20(1):7-24.

Bondhopadhyay B, Sisodiya S, Chikara A, et al. Cancer immunotherapy: a promising dawn in cancer research.

Am J Blood Res. 2020;10(6):375-385.

Fu C, Zhou L, Mi QS, Jiang A. DC-based vaccines for cancer immunotherapy. Vaccines (Basel). 2020;8(4):706. doi: 10.3390/vaccines8040706

Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportu- nities and challenges. Nat Rev Clin Oncol. 2018;15(5):325-340.

Ghansah T, Vohra N, Kinney K, et al. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother. 2013;62(6):1083- 1091.

Rojas-Canales D, Krishnan R, Jessup CF, Coates PT. Early exposure of interferon-γ inhibits signal transducer and activator of transcription-6 signalling and nuclear factor κB activation in a short-term monocyte-derived den- dritic cell culture promoting 'FAST' regulatory dendritic cells. Clin Exp Immunol. 2012;167(3):447-458. https://

Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that syner- gize with cancer immunotherapy. Cancer Cell Microenviron. 2015;2(1):e677.

De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunothera- py in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10): 3098-3104. https://doi. org/10.1158/1078-0432.CCR-07-4875

Yao Y, Luo F, Tang C, et al. Molecular subgroups and B7-H4 expression levels predict responses to dendrit- ic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunot­ her. 2018;67(11):1777-1788.

Wang QT, Nie Y, Sun SN, et al. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol Immunother. 2020;69(7):1375-1387.

Mitsuya K, Akiyama Y, Iizuka A, et al. Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: a phase II clinical trial. Anticancer Res. 2020;40(11):6473-6484. ticanres.14669

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. 016-1545-1

Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol. 2009;10: 459-466.

Skachkova ОV, Gorbach ОІ, Khranovska NM, et al. Immune monitoring of dendritic cell-based cancer vaccine in glioblastoma patients. World Med Biol. 2021;17(77):152-157. 152-157

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.

Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000;9(6):e8.

Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842-847.

Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973-4979. 5472.CAN-03-3505

Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;164:114954.

van Gulijk M, Dammeijer F, Aerts JGJV, Vroman H. Combination strategies to optimize efficacy of dendritic cell- based immunotherapy. Front Immunol. 2018;9:2759.

Li Y, Li S, Jiang Z, et al. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent ad- vances and future directions. J Nanobiotechnology. 2023;21(1):212.




How to Cite

Glavatskyi, O., Khranovska, N., Skachkova, O., Gorbach, O., Khmelnytskyi, H., Shuba, I., … Zemskova, O. (2023). DENDRITIC CELLS IN GLIOBLASTOMA TREATMENT: A MODERN VIEW OF THE PROBLEM AND OWN EXPERIENCE. Experimental Oncology, 45(3), 282–296.